University of Maryland, Baltimore
12 articles about University of Maryland, Baltimore
University of Maryland, Baltimore (UMB) Grants GlycoMantra Exclusive License to Advance the Company's Therapeutic Pipeline
GlycoMantra has been granted worldwide, exclusive rights to a UMB technology to advance the company's pipeline of therapeutics for treating drug-resistant metastatic colorectal cancer.
UM School of Medicine Dean Announces He Will Transition From The Deanship In 2022 After Completing 16-Year Tenure
Dr. Reece led the UMSOM through Period of Unprecedented Growth Across All Mission Areas; He Will Return to the UMSOM Faculty to Lead a New Center, and Continue Research and Teaching
Option for Treatment for Coronavirus Extended
AIkido Pharma Inc. announced it has extended its previously disclosed exclusive option agreement with the University of Maryland, Baltimore for the technology set forth in Patent number 10,434,116 "Methods of Treating Coronavirus Infection." The present invention provides methods for treating a coronavirus infection.
AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
AIkido Pharma Inc. announced that on April 13, 2020, the Company executed a Master License Agreement with the University of Maryland, Baltimore.
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
Hoth Therapeutics, Inc. announced that Hoth Therapeutics, Inc. (Hoth) has entered into a Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc.
Grant to improve biopharmaceuticals production goes to UMB researcher
National Institute for Innovation in Manufacturing Biopharmaceuticals Funds UMB Researcher
Targeting HIV: Moving closer to a potential cure
A team of researchers at IBBR is showing how engineered multi-specific antibodies appear to be highly effective at preventing infection across a broad range of HIV-1 virus strains.
University of Maryland, Baltimore Grants Pataigin, LLC, Rights To Technology Developed For Rapid, Point-Of-Care Identification Of Dangerous Pathogens
University of Maryland, Baltimore Grants Glycocept Rights To A Technology Designed To Increase The Efficacy Of Therapeutic Monoclonal Antibodies
Educational & Scientific, LLC And University of Maryland, Baltimore, Sign An Agreement To Develop And Commercialize Novel Treatment For Major Cancers
The University of Maryland, Baltimore and Paragon Bioservices Announce the Formation of a Public-Private Stem Cell Technology Consortium